重组人白介素-11衍生物对化疗所致血小板减少的疗效和安全性(20例)  

Efficacy and safety of recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapyinduced thrombocytopenia(20 cases)

作　　者：黄平[1] 陈占红[1] 曹文明[1] 黄健[1] 邵喜英[1] 蔡菊芬[1] 叶魏武[1] 郑亚兵[1] 王晓稼[1] 

机构地区：[1]浙江省肿瘤医院化疗中心,浙江杭州310022

出　　处：《临床药物治疗杂志》2012年第6期20-23,共4页Clinical Medication Journal

摘　　要：目的:观察预防性应用重组人白介素-11(rhIL-11)衍生物治疗化疗所致血小板减少的临床疗效与不良反应。方法:20例恶性肿瘤化疗后出现血小板减少的患者采用自身前后对照研究,对照周期接受化疗后未预防性使用rhIL-11衍生物,试验周期在化疗给药后6～48h内开始预防性应用rhIL-11衍生物,血小板计数300×109/L时停药,或出现血小板下降则使用至血小板计数100×109/L时停药。结果:各例患者使用重组人白介素-11衍生物的实际天数为3～15d,平均为5.2±3.2d,中位天数为4d。试验周期和对照周期血小板计数最低值分别为(57.6±20.6)×109/L和(78.2±29.7)×109/L,血小板减少持续时间分别为8.5±6.3d和5.7±6.3d。与对照周期相比,试验周期(化疗+rhIL-11衍生物)血小板最低值升高(P=0.00)、血小板计数<100×109/L持续时间缩短(P=0.03)。不良反应较轻(以Ⅰ～Ⅱ级为主),停药后能自行缓解,对患者凝血功能无影响。结论:rhIL-11衍生物对恶性肿瘤化疗所致血小板下降有确切的防治作用,且毒副作用耐受可逆、安全性良好。Objective： To investigate the clinical efficacy and adverse reaction of recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia in cancer patients. Method： A total of 20 cancer patients with chemotherapy-induced thrombocytopenia（≤75×109/L）were studied by self-cross control.In the control cycle the patients received chemotherapy, and rhlL-11 derivative was not given for prevention of thrombocytopenia, while in the treatment cycle, rhlL-11 derivative was given（1.5mg/d, subcutaneously）after 6h-48h of chemotherapy infusion until platelet count reached 〉300×l09/L.If thrombocytopenia happened, the rhlL-11 derivative was given until platelet count reached 〉100× 109/L.Result： The patients were treated with rhlL-11 derivative for actual-day number of 3 to 15 days, with an average of 5.2＋ 3.2 days, the median-day number of 4 days. The nadir platelet count was 57.6 ＋20.6 ×l 09/ L in the control cycle and 78.2＋ 29.7×109 / L in the treatment cycle. The days of platelet count less than 100×109/L were 8.5± 6.3 days in the control cycle and 5.7±6.3 days in the treatment cycle. Compared with the control cycle, treatment cycle （ chemotherapy ＋ rhlL-11 derivative） increased nadir platelet levels （ p=0.00 ）, and shorten the time of platelet count less than 100× 109/L （ p=0.03 ）. Adverse reactions were mild （ Ⅰ-Ⅱ）, mainly included fatigue, musculoskeletal pain, and could relieve itself after stopping rhlL-11 derivative,and there is no effect on the blood coagulation function. Conclusion： rhlL-11 derivative can be effectively used in the prevention and treatment of chemotherapy-induced thrombocytopenia in cancer patients with reversible slight side-effects and good tolerance.

关 键 词：rhIL-11衍生物 血小板减少 化疗 

分 类 号：R558.2[医药卫生—血液循环系统疾病]